The Power of Mid-Sized Numbers
Not so long ago, the mid-sized American drug company was a rare bird indeed. Thanks to its flexibility, it's now off the endangered list. The overvalued Big Pharmas, caught in their own tightening circles of strategic options, would do well to pay attention.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.